Background Most of the currently available inhaled beta-2 agonists are short acting bronchodilators. The aim of this study was to compare the rate of onset and duration of the bronchodilating activity of formoterol and salbutamol. Methods Fourteen patients with reversible airways obstruction received placebo, 200-mu-g salbutamol, and 12, 24, and 48-mu-g formoterol from a metered dose inhaler, according to a double blind, randomised crossover design. Forced expiratory volume in one second (FEV1) and specific airways conductance (sGaw) were measured over 12 hours. Results Salbutamol and all doses of formoterol caused a significant and substantial increase in sGaw one minute after inhalation. The mean maximum increase in FEV1 was SS% (8%) af...
AbstractThis single-centre, randomized, double-blind, double-dummy four-way cross-over study in 24 m...
ABSTRACT: This randomized, double-blind, placebo-controlled, crossover study was designed to investi...
Several clinical trials have shown that the inhaled beta2-agonists with long-acting properties, form...
Background Most of the currently available inhaled beta-2 agonists are short acting bronchodilators....
The aim of the study was to investigate the time of onset and the duration of the bronchodilating ef...
SummaryRationaleFormoterol is approved as asthma rescue medication in many countries. The exact dura...
AbstractFormoterol fumarate is a β2-agonist bronchodilator that combines a fast onset of action with...
RATIONALE: Formoterol is approved as asthma rescue medication in many countries. The exact duration ...
BACKGROUND AND OBJECTIVE: Long-acting beta(2)-agonists have acquired an indispensable position in th...
AbstractThe aim of the study was to investigate the time of onset and the duration of the bronchodil...
Ten subjects with various degrees of asthma severity underwent a three-day trial, with the aim of ev...
<p><strong><em>Backgrounds: </em></strong>All of Long-acting β2-agonists are beneficial in maintenan...
ABSTRACT: Continuous treatment with a short-acting b2-agonist can lead to reduced bronchodilator res...
We studied 16 patients with stable COPD in a double blind, double dummy, placebo-controlled, within ...
Virtually all asthma patients use bronchodilators. Formoterol and salbutamol have a rapid onset of b...
AbstractThis single-centre, randomized, double-blind, double-dummy four-way cross-over study in 24 m...
ABSTRACT: This randomized, double-blind, placebo-controlled, crossover study was designed to investi...
Several clinical trials have shown that the inhaled beta2-agonists with long-acting properties, form...
Background Most of the currently available inhaled beta-2 agonists are short acting bronchodilators....
The aim of the study was to investigate the time of onset and the duration of the bronchodilating ef...
SummaryRationaleFormoterol is approved as asthma rescue medication in many countries. The exact dura...
AbstractFormoterol fumarate is a β2-agonist bronchodilator that combines a fast onset of action with...
RATIONALE: Formoterol is approved as asthma rescue medication in many countries. The exact duration ...
BACKGROUND AND OBJECTIVE: Long-acting beta(2)-agonists have acquired an indispensable position in th...
AbstractThe aim of the study was to investigate the time of onset and the duration of the bronchodil...
Ten subjects with various degrees of asthma severity underwent a three-day trial, with the aim of ev...
<p><strong><em>Backgrounds: </em></strong>All of Long-acting β2-agonists are beneficial in maintenan...
ABSTRACT: Continuous treatment with a short-acting b2-agonist can lead to reduced bronchodilator res...
We studied 16 patients with stable COPD in a double blind, double dummy, placebo-controlled, within ...
Virtually all asthma patients use bronchodilators. Formoterol and salbutamol have a rapid onset of b...
AbstractThis single-centre, randomized, double-blind, double-dummy four-way cross-over study in 24 m...
ABSTRACT: This randomized, double-blind, placebo-controlled, crossover study was designed to investi...
Several clinical trials have shown that the inhaled beta2-agonists with long-acting properties, form...